Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Treasury Shares (2023 - 2026)

Prelude Therapeutics' Treasury Shares history spans 4 years, with the latest figure at $439080.0 for Q1 2026.

  • On a quarterly basis, Treasury Shares rose 14.08% to $439080.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $439080.0, a 14.08% increase, with the full-year FY2025 number at $220500.0, up 292.0% from a year prior.
  • Treasury Shares hit $439080.0 in Q1 2026 for Prelude Therapeutics, up from $220500.0 in the prior quarter.
  • Over the last five years, Treasury Shares for PRLD hit a ceiling of $439080.0 in Q1 2026 and a floor of $56250.0 in Q4 2024.
  • Historically, Treasury Shares has averaged $208208.0 across 4 years, with a median of $162125.0 in 2023.
  • Biggest five-year swings in Treasury Shares: crashed 45.78% in 2024 and later soared 313.29% in 2025.
  • Tracing PRLD's Treasury Shares over 4 years: stood at $103750.0 in 2023, then crashed by 45.78% to $56250.0 in 2024, then skyrocketed by 292.0% to $220500.0 in 2025, then soared by 99.13% to $439080.0 in 2026.
  • Business Quant data shows Treasury Shares for PRLD at $439080.0 in Q1 2026, $220500.0 in Q4 2025, and $292375.0 in Q3 2025.